

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APR 19 2007

(use as many sheets as necessary)

**COMPLETE IF KNOWN**

|                           |            |
|---------------------------|------------|
| <b>Application Number</b> | 10/579,596 |
|---------------------------|------------|

|                    |              |
|--------------------|--------------|
| <b>Filing Date</b> | May 17, 2006 |
|--------------------|--------------|

|                             |               |
|-----------------------------|---------------|
| <b>First Named Inventor</b> | Harada et al. |
|-----------------------------|---------------|

|                |      |
|----------------|------|
| Group Art Unit | 1647 |
|----------------|------|

|               |    |
|---------------|----|
| Examiner Name | -- |
|---------------|----|

|                        |         |
|------------------------|---------|
| Attorney Docket Number | 21351YP |
|------------------------|---------|

Sheet

**1**

of

3

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent Document |                                       | Name of Patentee or Applicant of Cited Document                                  | Date of Publication of Cited Document<br>MM-DD-YYYY |
|--------------------|----------|-------------------------|---------------------------------------|--|---|
|                    |          | Office                  | Number<br><br>Kind Code<br>(if known) |  |   |
|                    |          |                         | WO 02/092015                          | Genome Therapeutics Corporation/Wyeth  | 11/21/2002  |
|                    |          |                         | WO 00/52047                           | Millennium Pharmaceuticals, Inc.   | 09/08/2000  |
|                    |          |                         | WO 99/22000                           | Deutsches Krebsforschungszentrum Stiftung des<br>Öffentlichen Rechts             | 05/06/1999  |
|                    |          |                         | WO 98/46755                           | Millennium Biotherapeutics, Inc.   | 10/22/1998  |
|                    |          |                         | WO 98/46743                           | The Wellcome Trust Limited as trustee to The<br>Wellcome Trust/Merck & Co., Inc. | 10/22/1998  |
|                    |          |                         |                                       |  |   |
|                    |          |                         |                                       |  |   |
|                    |          |                         |                                       |  |   |
|                    |          |                         |                                       |  |   |
|                    |          |                         |                                       |  |   |
|                    |          |                         |                                       |  |   |

Examiner  
Signature

/Daniel Gamett/ (01/15/2008)

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Committee generated from TDS Form 1 (older), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(use as many sheets as necessary)



### COMPLETE IF KNOWN

|                        |               |
|------------------------|---------------|
| Application Number     | 10/579,596    |
| Filing Date            | May 17, 2006  |
| First Named Inventor   | Harada et al. |
| Group Art Unit         | 1647          |
| Examiner Name          | --            |
| Attorney Docket Number | 21351YP       |

Sheet 2 of

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. | Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.  |
|--------------------|----------|---|
|                    | AA       | Bafico et al., Nature Cell Biology, Vol. 3 (2001), pp. 683-686, "Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow"   |
|                    | AB       | Bennett et al., J. of Biol. Chem., Vol. 277 (2002), pp. 30998-31004, "Regulation of Wnt signaling during adipogenesis"  |
|                    | AC       | Boyden et al., N. Eng. J. of Med., Vol. 346 (2002), pp. 1513-1521, "High bone density due to a mutation in LDL-receptor-related protein 5"  |
|                    | AD       | Davidson et al., Development, Vol. 129 (2002), pp. 5587-5596, "Kremen proteins interact with Dickkopf1 to regulate anteroposterior CNS patterning"  |
|                    | AE       | Fujino et al., PNAS, Vol. 100 (2003), pp. 229-234, "Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion"                           |
|                    | AF       | Glinka et al., Nature, Vol. 391 (1998), pp. 357-362, "Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction"  |
|                    | AG       | Gong et al., Cell, Vol. 107 (2001), pp. 513-523, "LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development"   |
|                    | AH       | Hey et al., Gene, Vol. 216 (1998), pp. 103-111, "Cloning of a novel member of the low-density lipoprotein receptor family"  |
|                    | AK       | Hsu et al., Molecular and Cellular Biol., Vol. 18 (1998), pp. 4807-4818, "Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with beta-catenin"                                 |
|                    | AL       | Katagiri et al., J. of Cell Biology, Vol. 127 (1994), pp. 1755-1766, "Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage"                                       |
|                    | AK       | Kato et al., J. of Cell Biology, Vol. 157 (2002), pp. 303-314, "Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor" |
|                    | AL       | Krupnik et al., Gene, Vol. 238 (1999), pp. 301-313, "Functional and structural diversity of the human Dickkopf gene family"   |
|                    | AM       | Li et al., The EMBO Journal, Vol. 18 (1999), pp. 4233-4240, "Axin and Frat1 interact with Dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1"   |
|                    | AN       | Little et al., Am. J. Hum. Genet., Vol. 70 (2002), pp. 11-19, "A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait"  |
|                    | AO       | Magoori et al., J. of Biol. Chem., Vol. 278 (2003), pp. 11331-11336, "Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related ..."    |

Examiner Signature

/Daniel Gamett/ (01/15/2008)


Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

Computer generated form (DS Form) (IDS Folder) Mark & Co., Inc., 8/24/2006

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/

|  |   |                          |               |
|--|---|--------------------------|---------------|
| Substitute for form 1449B/PTO  |   | <b>COMPLETE IF KNOWN</b> |               |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   | Application Number       | 10/579,596    |
|  |   | Filing Date              | May 17, 2006  |
|  |   | First Named Inventor     | Harada et al. |
|  |   | Group Art Unit           | 1647          |
|  |   | Examiner Name            | --            |
|  |   | Attorney Docket Number   | 21351YP       |
| Sheet  | 3 | 3                        |               |

| NON PATENT LITERATURE DOCUMENTS |          |   |
|---------------------------------|----------|---|
| Examiner Initials*              | Cite No. | Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.  |
|                                 | AP       | Mao et al., Gene, Vol. 302 (2003), pp. 179-183, Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling"   |
|                                 | AQ       | Mao et al., Molecular Cell, Vol. 7 (2001), pp. 801-809, "Low-density lipoprotein receptor-related protein-5 binds to axin and regulates the canonical Wnt signaling pathway"                                  |
|                                 | AR       | Mao et al., Nature, Vol. 411 (2001), pp. 321-325, "LDL-receptor-related protein 6 is a receptor for Dickkopf proteins"  |
|                                 | AS       | Mao et al., Nature, Vol. 410 (2002), pp. 664-667, "Kremen proteins are Dickkopf receptors that regulate Wnt/beta-protein signaling"   |
|                                 | AT       | Patel et al., N. Eng. J. Med., Vol. 346 (2002), pp. 1572-1574, "Regulation of bone formation and vision by LRP5"  |
|                                 | AU       | Semenov et al., Current Biology, Vol. 11 (2001), pp. 951-961, "Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6"   |
|                                 | AV       | Sjolander et al., Anal. Chem., Vol. 63 (1991), pp. 2338-2345, "Integrated fluid handling system for biomolecular interaction analysis"  |
|                                 | AW       | Szabo et al., Current Opin. in Structural Biol., Vol. 5 (1995), pp. 699-705, "Surface plasmon resonance and its use in biomolecular interaction analysis (BIA)"   |
|                                 | AX       | Yuan et al., J. of Biol. Chem., Vol. 274 (1999), pp. 30419-30423, "Suppression of glycogen synthase kinase activity is not sufficient for leukemia enhancer factor-1 activation"                              |
|                                 | AY       | Yamaguchi et al., Biochem. and Biophys. Res. Comm., Vol. 220 (1996), pp. 366-371, "Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and ..." |
|                                 |          |   |
|                                 |          |   |
|                                 |          |   |
|                                 |          |   |
|                                 |          |   |
|                                 |          |   |

|                    |                               |                 |  |
|--------------------|-------------------------------|-----------------|--|
| Examiner Signature | /Daniel Garnett/ (01/15/2008) | Date Considered |  |
|--------------------|-------------------------------|-----------------|--|

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.